CIP
ALT icon

Chartwell Investment Partners’s Altimmune ALT Stock Holding History

Chartwell Investment Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-53,294
Closed -$624K – 413
2022
Q2 		$624K Buy
+53,294
New +$329K 0.03% 387

Other funds holding ALT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Chartwell Investment Partners's ALT Position: Q3 2022 in Review

Chartwell Investment Partners sold out of Altimmune (ALT) in Q3 2022, closing a stake of 53,294 shares — an estimated $624K sold.

Chartwell Investment Partners first reported a position in ALT in Q2 2022 and held it in 1 quarter. The position peaked at $624K in Q2 2022. 122 funds tracked by Wall St. Rank hold ALT as of Q3 2022.

  • Chartwell Investment Partners reported no remaining Altimmune position as of Q3 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 53,294 Altimmune shares in Q3 2022, an estimated $624K.
  • Chartwell Investment Partners first reported a position in Altimmune in Q2 2022 and held it in 1 quarter.
  • Chartwell Investment Partners's Altimmune position peaked at $624K in Q2 2022.
  • 122 funds tracked by Wall St. Rank held Altimmune as of Q3 2022.

Based on Chartwell Investment Partners's 13F filing for Q3 2022, filed 27 Oct 2022.